Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Brescia – page 43

561 clinical trials in Brescia, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Brescia at a glance
561
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

561 trials in Brescia

Open in trial search

Peripheral T-cell lymphoma unspecified

Not recruiting

Study on Brentuximab Vedotin and Drug Combination for Patients with Peripheral T-cell Lymphoma with Less Than 10% CD30 Expression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Seagen Inc.

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Camurus AB

Acute myeloid leukaemia

Not recruiting

Study of Venetoclax and Azacitidine for Patients with Acute Myeloid Leukemia After Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Chronic hepatitis B+1

Not recruiting

Study of Bepirovirsen for Patients with Chronic Hepatitis B on Nucleos(t)ide Analogue Treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Class III or IV Lupus Nephritis

Not recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:F. Hoffmann-La Roche AG

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Lung disorder

Not recruiting

Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Oslo University Hospital HF

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Lung disorder

Not recruiting

Study on the Effectiveness and Safety of Bemcentinib for Hospitalized Patients with Moderate COVID-19

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bemcentinib
  • Sponsor:Oslo University Hospital HF

Gastrointestinal stromal tumour

Not recruiting

Study of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Cogent Biosciences Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Brescia

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on metastatic colorectal cancer, chronic myeloid leukemia, and renal cell carcinoma. Studies evaluate novel combination therapies and treatment strategies for advanced cancer cases.

  • Colorectal Cancer Treatment
  • Leukemia Therapies
  • Advanced Renal Cancer

Research includes evaluation of targeted therapies and immunotherapy approaches.

02 Neurological Disorders

Comprehensive studies addressing Parkinson's disease, Frontotemporal Dementia, and Alzheimer's-related psychosis. Research focuses on novel therapeutic approaches and disease-modifying treatments.

  • Early-Stage Parkinson's Treatment
  • Dementia Management
  • Neurological Drug Development

Trials aim to improve patient outcomes and quality of life.

03 Autoimmune Conditions

Groundbreaking research in Psoriatic Arthritis, Crohn's Disease, and Sjögren's Syndrome. Studies evaluate biological therapies and innovative treatment approaches.

  • Inflammatory Disease Management
  • Autoimmune Response Modulation
  • Novel Therapeutic Approaches

Focus on developing targeted treatments for chronic conditions.

04 Cardiovascular Research

Studies addressing heart failure prevention and cardiovascular disease. Research evaluates new combination therapies and preventive approaches.

  • Heart Failure Prevention
  • Cardiovascular Risk Reduction
  • Therapeutic Combinations

Emphasis on preventive strategies and innovative treatments.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.